Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States.
High growth potential with adequate balance sheet.
Share Price & News
How has Pacira BioSciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 82P's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 82P underperformed the German Pharmaceuticals industry which returned -8.2% over the past year.
Return vs Market: 82P exceeded the German Market which returned -17.2% over the past year.
Price Volatility Vs. Market
How volatile is Pacira BioSciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Pacira BioSciences undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 82P (€30.4) is trading below our estimate of fair value (€122.52)
Significantly Below Fair Value: 82P is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 82P is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: 82P is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 82P's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 82P is overvalued based on its PB Ratio (4x) compared to the DE Pharmaceuticals industry average (1.7x).
How is Pacira BioSciences forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 82P is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).
Earnings vs Market: 82P is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 82P's is expected to become profitable in the next 3 years.
Revenue vs Market: 82P's revenue (12% per year) is forecast to grow faster than the German market (4.1% per year).
High Growth Revenue: 82P's revenue (12% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 82P's Return on Equity is forecast to be high in 3 years time (24.7%)
How has Pacira BioSciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 82P is currently unprofitable.
Growing Profit Margin: 82P is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 82P is unprofitable, but has reduced losses over the past 5 years at a rate of 1.3% per year.
Accelerating Growth: Unable to compare 82P's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 82P is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.9%).
Return on Equity
High ROE: 82P has a negative Return on Equity (-3.1%), as it is currently unprofitable.
How is Pacira BioSciences's financial position?
Financial Position Analysis
Short Term Liabilities: 82P's short term assets ($408.6M) exceed its short term liabilities ($107.7M).
Long Term Liabilities: 82P's short term assets ($408.6M) exceed its long term liabilities ($368.4M).
Debt to Equity History and Analysis
Debt Level: 82P's debt to equity ratio (86.2%) is considered high.
Reducing Debt: 82P's debt to equity ratio has increased from 60.4% to 86.2% over the past 5 years.
Inventory Level: 82P has a high level of physical assets or inventory.
Debt Coverage by Assets: 82P's debt is covered by short term assets (assets are 1.3x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 82P has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 82P is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 64.7% per year.
What is Pacira BioSciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 82P's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 82P's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 82P's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 82P's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 82P's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dave Stack (69yo)
Mr. David M. Stack, also known as Dave, has been the Chief Executive Officer of Pacira Pharmaceuticals Inc. Since 2007, Mr. Stack has served as Chief Executive Officer and Chairman of Pacira Pharmaceutical ...
CEO Compensation Analysis
Compensation vs Market: Dave's total compensation ($USD5.84M) is above average for companies of similar size in the German market ($USD1.85M).
Compensation vs Earnings: Dave's compensation has increased whilst the company is unprofitable.
|Chairman & CEO||12.42yrs||US$5.84m||0.34% $4.4m|
|Chief Financial Officer||3.92yrs||US$1.41m||0.0091% $115.9k|
|Chief Administrative Officer & Secretary||5.5yrs||US$1.94m||no data|
|Chief Commercial Officer||1.67yrs||US$2.53m||0.0067% $85.5k|
|President||0.83yr||no data||no data|
|Principal Accounting Officer & VP of Finance||8.08yrs||US$288.82k||0.010% $134.0k|
|Chief Technical Officer||1.33yrs||no data||0.0039% $49.2k|
|Head of Investor Relations||no data||no data||no data|
|Vice President of Human Resources||4.75yrs||no data||no data|
Experienced Management: 82P's management team is considered experienced (3.9 years average tenure).
|Chairman & CEO||12.42yrs||US$5.84m||0.34% $4.4m|
|Independent Director||8.83yrs||US$205.42k||0.011% $140.6k|
|Lead Director||6.83yrs||US$218.42k||0.0065% $83.5k|
|Independent Director||11.83yrs||US$180.22k||0.13% $1.7m|
|Independent Director||13.33yrs||no data||no data|
|Independent Director||12.75yrs||US$202.42k||0.029% $375.7k|
|Independent Director||6.83yrs||US$190.42k||0.024% $312.3k|
|Independent Director||6.08yrs||US$184.42k||0.013% $171.1k|
|Director||0.58yr||no data||no data|
|Independent Director||2.83yrs||US$175.42k||0.0014% $17.6k|
Experienced Board: 82P's board of directors are considered experienced (6.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 82P insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Pacira BioSciences, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Pacira BioSciences, Inc.
- Ticker: 82P
- Exchange: DB
- Founded: 2006
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.409b
- Listing Market Cap: US$1.277b
- Shares outstanding: 42.03m
- Website: https://www.pacira.com
Number of Employees
- Pacira BioSciences, Inc.
- 5 Sylvan Way
- Suite 300
- New Jersey
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PCRX||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Feb 2011|
|82P||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 2011|
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company has collaboration with Aetna. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/01 03:10|
|End of Day Share Price||2020/03/31 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.